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Recurrent Episodes of Rhabdomyolysis after Seizures  
in a Patient with Glycogen Storage Disease Type V
Dear Editor,
Glycogen storage disease type V (GSD-V) is the most common disorder of muscle glyco-
genosis and is caused by alterations in the PYGM gene.1 Patients with GSD-V typically pres-
ent with exercise intolerance, episodic rhabdomyolysis, and the second-wind phenomenon. 
Seizure has been well described as a provocative event for rhabdomyolysis, but it is not clas-
sical feature of GSD-V. Here we report recurrent episodes of rhabdomyolysis after seizures in 
a Korean patient with PYGM mutations.
The male proband (II-2 in Fig. 1A) was the first child of nonconsanguineous healthy par-
ents. He achieved normal motor milestones. At the age of 17 years he was hospitalized for 
rhabdomyolysis with a serum creatine kinase (CK) level of 718,000 IU/L after intense exer-
cise and generalized tonic-clonic seizure (Supplementary Table 1 in the online-only Data Sup-
plement). He did not have fixed muscle weakness. An electromyography study showed no 
spontaneous activities. Electroencephalography demonstrated a few spikes at the left fron-
tocentral region. He was hydrated, and treated with anticonvulsants, but the serum CK level 
remained elevated (630 IU/L) at rest. The ischemic forearm exercise test demonstrated no 
increase in serum lactate level and a normal increase in serum ammonia level. At the age of 
18 years he was readmitted to our clinic due to rhabdomyolysis and seizure. His serum CK 
level was 486,800 IU/L. Subtle muscle weakness was initially found in the shoulder girdle 
muscles, but recovered after 3 days. At the age of 28 years he was hospitalized for the third 
event of rhabdomyolysis (serum CK level: 124,500 IU/L) after a seizure. We performed tar-
geted sequencing of 69 myopathy-related genes, including PYGM (Supplementary Table 2 
and 3 in the online-only Data Supplement). DNA fragments in the target regions were en-
riched by solution-based hybridization capture, followed by sequencing with the Illumina 
Hiseq2000 platform. The sequencing data were analyzed using a standard pipeline (see in 
Supplementary Information in the online-only Data Suplement). Variants were then filtered 
further based on the patient’s phenotype. We identified compound heterozygous PYGM mu-
tations of c.1531delG and c.1999A>T (Fig. 1B). The c.1531delG mutation has been reported 
previously,2 but the c.1999A>T mutation is novel, since it was not detected in dbSNP138 or 
the 1000 Genomes Database (September 2014 release). In silico predictions support a dele-
terious effect of the c.1999A>T mutation on PYGM (Supplementary Table 4 in the online-
only Data Supplement). Additionally, genomic evolutionary rate profiling indicated that the 
affected nucleotide is highly conserved (score=4.91) (Fig. 1C). Thus, we determined that 
the c.1531delG and c.1999A>T compound heterozygous PYGM mutations were the under-
lying cause of the observed myopathy. A deltoid muscle biopsy was performed at the age of 
18 years. Light microscopy of the sample with hematoxylin and eosin staining revealed 
moderate variations of fiber size and shape as well as numerous scattered markedly necrotic 
myofibers with macrophage infiltration (Fig. 1D). The periodic acid-Schiff stain showed a 
slightly increased positive reaction in the remaining myofibers. Electron microscopy re-
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vealed the focal subsarcolemmal accumulation of glycogen 
(Fig. 1E) and necrotic myofibers exhibiting variable stages of 
degenerative changes (Fig. 1F). 
We have identified compound heterozygous PYGM muta-
tions (c.1531delG and c.1999A>T) using targeted sequencing 
of 69 myopathy-related genes. GSD-V is caused by a deficien-
cy of the muscle isoform of phosphorylase, which is encoded 
by PYGM. Human phosphorylase consists of three isoforms 
that are differentially expressed in the muscle, brain, and liver, 
with the muscle isoform being mainly expressed in muscle 
tissue. Therefore, GSD-V is usually considered to be a pure 
myopathy. However, both the brain and muscle isoforms 
were expressed in astrocytes, which predominantly contain 
glycogen in the adult brain.3 The occurrence of seizures has 
rarely been reported in patients with GSD-V,1,4 which suggests 
that the muscle isoform has an additional role in the brain; 
however, the precise nature of this role remains to be deter-
mined.
In conclusion, this is the first report of novel compound het-
erozygous PYGM mutations in a Korean patient with recur-
rent seizure as rare provocative events of rhabdomyolysis.
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Fig. 1. Pedigree, sequencing chromatograms, conservation profile, and pathology. A: Pedigree of a Korean patient with compound heterozygous 
PYGM mutations. Arrows indicates the proband (square: male; circle: female; filled: affected; and nonfilled: unaffected). B: Sequencing chromato-
grams of PYGM mutations c.1531delG (p.D511fs) and c.1999A>T (p.I667F). Arrows indicate mutation sites. C: Conservation analysis of the amino 
acid sequence at the p.I667F mutation site, which was well conserved among the subset of species studied. D, E, and F: Histopathologic examina-
tion of a deltoid muscle. D: Hematoxylin and eosin (H-E) stain revealed moderate variations of fiber size and shape, and the presence of many 
scattered necrotic myofibers with macrophage infiltration. E and F: Electron microscopy revealed focal subsarcolemmal accumulation of glycogen 
(E) and necrotic myofibers exhibiting variable stages of degenerative changes (F) (D: H-E stain, ×200, E: EM, ×6,000, F: EM, ×7,000).
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